ArticlePloS one2025
Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate whether early axial length (AL) changes in the short term after 0.125% atropine treatment could predict long-term axial elongation in children with myopia.
methodsThis was a prospective cohort study involving children aged 5-15 years with myopia who were treated with 0.125% atropine for myopia control. AL was measured 1-2 months after starting treatment and then every 3 months for follow-up visits. Regression analysis was used to develop a model of AL changes with time. A generalized estimating equation (GEE) model was then used to identify correlations between the early AL changes and long-term AL changes.
resultsEighty eyes of 40 patients (mean age 8.4 years) were included in the final analysis. The estimation curve of AL changes with time indicated that the AL decreased at 67 days (the turning point in the regression model) after 0.125% atropine treatment and then increased gradually with time. Univariate GEE showed that a larger AL elongation in the initial 4 months was significantly associated with AL changes at 6 months (β = 0.354, P = 0.020, 6 ~ 12 months period from baseline) and 12 months (β = 0.560, P = 0.045, 6 ~ 18 months period from baseline) after that period in all myopic eyes.
conclusionsThe magnitude of AL elongation in the initial 4 months of 0.125% atropine treatment correlated positively with the further half-year and one-year AL changes. Identifying these changes may be useful for controlling refractory myopia in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.